Connor, Clark & Lunn Investment Management (CC&L)’s Protagonist Therapeutics PTGX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87M	Buy	27,260 +13,990	+105%	+$1.24M	0.01%	851
2025 Q4	$1.16M	Buy	+13,270	New	+$1.09M	﹤0.01%	1089
2024 Q3	–	Sell	-82,791	Closed	-$2.87M	–	1604
2024 Q2	$2.87M	Sell	82,791 -10,395	-11%	-$304K	0.01%	560
2024 Q1	$2.7M	Sell	93,186 -14,356	-13%	-$391K	0.01%	593
2023 Q4	$2.47M	Sell	107,542 -31,952	-23%	-$559K	0.01%	616
2023 Q3	$2.33M	Sell	139,494 -23,931	-15%	-$464K	0.01%	576
2023 Q2	$4.51M	Buy	163,425 +41,401	+34%	+$1.04M	0.02%	419
2023 Q1	$2.81M	Sell	122,024 -72,680	-37%	-$1.22M	0.02%	486
2022 Q4	$2.12M	Buy	194,704 +3,511	+2%	+$29.6K	0.01%	526
2022 Q3	$1.61M	Buy	+191,193	New	+$1.81M	0.01%	539
2020 Q3	–	Sell	-28,598	Closed	-$505K	–	1085
2020 Q2	$505K	Buy	+28,598	New	+$359K	﹤0.01%	755